Skip to content
Screener

Innoviva, Inc. INVA Accrued Expenses

Accrued Expenses at other companies

Merck & Co. logo
Merck & Co.MRK
$14.73B+1.5%
Savara logo
SavaraSVRA
$10.6M+19.4%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$16.17M+91.3%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$7.83M+7.8%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$5.09M+2,222%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$4.64M+84.4%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.49B+20.6%
Enterprise value$1.19B-7.6%
P/E4.2×-27.8×
P/S3.4×+0.1×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
Line itemJune 30, 2026 / (Unaudited)December 31, 2025 / *
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$4,016$4,966
Accrued personnel-related expenses6,8029,100
Accrued interest payable1,6181,618
Deferred revenue6,0154,270
Income tax payable274
Other accrued liabilities28,61329,468

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s accrued expenses?
Innoviva, Inc. (INVA) reported accrued expenses of $6.8M in Q2 2026.
How has Innoviva, Inc.'s accrued expenses changed year-over-year?
Innoviva, Inc.'s accrued expenses increased by 43.2% year-over-year, from $4.75M to $6.8M.
What is the long-term trend for Innoviva, Inc.'s accrued expenses?
Over 5 years (2020 to 2025), Innoviva, Inc.'s accrued expenses has grown at a 79.4% compound annual growth rate (CAGR), from $490K to $9.1M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.

Ask your AI about Innoviva, Inc.'s accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude